5Saour JN, Sieck JO,Rahimmamo LA, et al. Trial of different intensities of anticoagulation in patients with prosthetic heart valves[J]. N Engl J Med, 1990,322(7) :428 - 432.
6Van Nooten GJ, Van Belleghem Y, Caes F, et al. Lower- intensity anticoagulation for mechanical heart valves: a new concept with the ATS bileaflet aortic valve[J]. J Heart Valve Dis. 2003,12(4) :495 - 501.
4Callo L, Ruiz B, Nistal F,et al. Degeneration in porcine bioprosthesis cardiac valves: Incidence of primary tissue failure among 938 bioprosthesis at risk. AM J Cardioll, 1984,53:1061.
5Perle RP, Deloche A, Chauvaud S. Comparative evaluation of mitral valve repair and replacement with starr, Bjork, and porcine valve prostheses. Circulation, 1984,70(12) : 1-187.
6Marshall WG, Kouchoukos NT, Karp RB, et al. Cate results after mitral valve replacement with the Bjork-shiley and porcine prosthess .J Thorac Cardiovasc Surg, 1983,85(6) :902.
7Boucher CA, Bingham JB, Osbakken Mb, et al. Early changes in ventricular size and function after correction of left ventricular volume overload. Am J Cardiol, 1981,47:991.
8Shaul W1, Hall JG. Multiple congenital anomalies associated with oval anticoagulants. Am J ovstet Gynecol, 1977,123 : 191.
9Born D, Marinez EE, Almaida PA, et al. Pregnancy in patients with prosthetic heart valves: the effect of anticoagnlation on mother, fetus, and neonate. Am Heart J, 1992,124(2) :413.
10Ansell JE. Oral anticoagulant the rapy-50 years later, arch intemmen, 1993,153:586.
3Butchart EG,Lewis PA,Bethel JA. Adjusting anticoagulation to pros-thesis thrombogenicity and paitent risk-factors[J].Recommendations for the Medtronic Hall valve@Circulation,1991,(Suppl 5):61.
